Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Alector, Inc.
ALEC · SEC Filings
website
103
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of...
Price
2.46
Market Cap
366.24 M
Float
142.65 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about ALEC
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Alector, Inc.
ALEC · SEC Filings
142.65 M
Float
2.46
Price
366.24 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 5, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 6, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 7, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 25, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 6, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 7, 2025
News
TYPE
HEADLINE
FILED AT
8-K
Alector Reports Third Quarter 2026 Financial Results, Business Updates, and Genentech Licensing Agreement
Nov 5, 2026
8-K
Alector Announces Pricing of Underwritten Offering of Common Stock
Oct 16, 2026
8-K
Alector, Inc. Approves Stock Option Repricing for Current Employees and Executives
Oct 14, 2026
8-K
Alector Enters License Agreement with Genentech for AL050 Program and Exercises Option with Spur Therapeutics
Oct 5, 2026
8-K
Alector Reports Second Quarter 2026 Financial Results and Pipeline Progress
Aug 6, 2026
8-K
Alector, Inc. Announces Termination of GSK Collaboration and Repayment of Loan Agreement
Jul 8, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B5
REGISTERED OFFERING
Oct 16, 2026
424B5
[No Baby Shelf]* May 2026 ATM | Offering amount: $125,000,000 | Bank: TD Securities (USA) LLC
May 7, 2026
424B5
SHELF OFFERING | Shares amount: 10,869,566 | Share price: $6.57 | Offering amount: $71,400,000.00
Jan 19, 2024
424B5
Shares of Common Stock
Jan 16, 2024
424B5
ATM | Offering amount: $125,000,000
Nov 7, 2023
424B5
Common Stock
May 13, 2020
Registrations
TYPE
HEADLINE
FILED AT
FWP
OFFERING
Oct 16, 2026
S-3
March 2026 SHELF
Mar 12, 2026
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Feb 25, 2026
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Feb 26, 2025
S-8
Registration
Feb 27, 2024
POS AM
Registration
May 2, 2023
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 28, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 28, 2026
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 24, 2025
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2024
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 25, 2024
Ownerships
TYPE
HEADLINE
FILED AT
SCHEDULE 13G
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Oct 26, 2026
SCHEDULE 13G
Deep Track Capital, LP (Filed by)
Oct 23, 2026
4
Rosenthal Arnon (Reporting)
Oct 15, 2026
4
Wong-Sarad Grace (Reporting)
Oct 15, 2026
4
Berkley Neil Lindsay (Reporting)
Oct 15, 2026
SCHEDULE 13G
BIOTECHNOLOGY VALUE FUND L P (Filed by)
Sep 18, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
May 1, 2026
CORRESP
Form CORRESP - Correspondence
Apr 28, 2026
LETTER
Form UPLOAD - SEC-generated letter
Mar 17, 2026
EFFECT
Form EFFECT - Notice of Effectiveness
May 8, 2023
EFFECT
Form EFFECT - Notice of Effectiveness
May 2, 2023
CORRESP
Form CORRESP - Correspondence
Apr 27, 2023
